Protocol core needle biopsy and histological chronic allograft damage index as surrogate endpoint for Long-Term graft survival.

[1]  T. Paavonen,et al.  Protocol core needle biopsy and histologic Chronic Allograft Damage Index (CADI) as surrogate end point for long-term graft survival in multicenter studies. , 2003, Journal of the American Society of Nephrology : JASN.

[2]  P. Hayry,et al.  Elimination of vascular fibrointimal hyperplasia bysomatostatin receptor 1.4 selective agonist , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  J. Gustafsson,et al.  Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors α and β , 1999 .

[4]  E. Buchdunger,et al.  Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. , 1999, Circulation.

[5]  M. M. Rees,et al.  Mycophenolate mofetil in cadaveric renal transplantation , 1999 .

[6]  T. Mathew.  A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. , 1998, Transplantation.

[7]  E. Buchdunger,et al.  Inhibition of platelet‐derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  G. Remuzzi,et al.  A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. , 1996, Transplantation.

[9]  L. Hunsicker,et al.  Design of trials of methods to reduce late renal allograft loss: the price of success. , 1995, Kidney international. Supplement.

[10]  Sollinger Hw.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995 .

[11]  B. Fellström,et al.  Can histopathological findings in early renal allograft biopsies identify patients at risk for chronic vascular rejection? , 1995, Clinical transplantation.

[12]  R. Lieberman,et al.  Principles of drug development in transplantation and autoimmunity , 1995 .

[13]  H. Isoniemi,et al.  HISTOLOGICAL CHRONIC ALLOGRAFT DAMAGE INDEX ACCURATELY PREDICTS CHRONIC RENAL ALLOGRAFT REJECTION , 1994, Transplantation.

[14]  T. Paavonen,et al.  Chronic rejection of rat renal allograft , 1992, Transplant international : official journal of the European Society for Organ Transplantation.

[15]  B. Kasiske,et al.  Histopathologic findings associated with a chronic, progressive decline in renal allograft function. , 1991, Kidney international.